Search
Veltuzumab
go.drugbank.com/drugs/DB05656InvestigationalVeltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Faropenem medoxomil
go.drugbank.com/drugs/DB05659InvestigationalFaropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.
Categories: Heterocyclic Compounds, 2-RingLevoketoconazole
go.drugbank.com/drugs/DB05667ApprovedIt possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate. … Still, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].
Categories: MATE 1 Inhibitors, P-glycoprotein inhibitorsOP-145
go.drugbank.com/drugs/DB05672ExperimentalOP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.
Synonyms: (4S)-4-(((2S)-2-((2-(((2S,3S)-2-ACETAMIDO-3-METHYL-PENTANOYL)AMINO)ACETYL)AMINO)-6-AMINO-HEXANOYL)AMINO)-5-(((1S)-2-(((1S)-5-AMINO-1-(((1S)-1-(((1S,2S)-1-(((1S)-1-(((1S)-1-(((1S)-1-(((1S,2S)-1-(((1S)-5, -AMINO-1-(((1S)-1-(((1S)-1-BENZYL-2-(((1S)-1-(((1S)-1NV-52
go.drugbank.com/drugs/DB05673ExperimentalNV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.
FX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.
Quinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnQuinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer. … Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia.
Categories: Heterocyclic Compounds, 2-RingSynonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideSomatrem
go.drugbank.com/drugs/DB09098ApprovedWithdrawnSuch discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when
Elvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalElvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. … Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation
Mixtures: GENVOYA ® TABLETAS RECUBIERTAS, STRIBILD® TABLETAS RECUBIERTASCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InducersAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc. The annual average price of Asfotase Alfa treatment is $285,000. … Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).